HiJAKing Immunotherapy-Resistant Melanoma for a Cure

Abstract Immune checkpoint blockers (ICBs) have brought great promise to patients with advanced melanoma, a tumor type that was claimed largely incurable not long ago. However, therapeutic resistance to ICBs has limited their utility in the clinic. Here, we provide a commentary on recent research en...

Full description

Saved in:
Bibliographic Details
Published in:The oncologist (Dayton, Ohio) Ohio), 2023-03, Vol.28 (3), p.196-198
Main Authors: Shi, Lewis Zhichang, Shen, Hongxing, Ojo, Oluwagbemiga A, Bonner, James A
Format: Article
Language:English
Subjects:
Cancer
Care and treatment
Commentaries
Development and progression
Dosage and administration
Drug approval
Drug Resistance, Neoplasm
Drug therapy
Health aspects
Humans
Immune Checkpoint Inhibitors - pharmacology
Immune Checkpoint Inhibitors - therapeutic use
Immunotherapy
Ipilimumab
Melanoma
Melanoma - drug therapy
Monoclonal antibodies
Patient outcomes
Skin cancer
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Immune checkpoint blockers (ICBs) have brought great promise to patients with advanced melanoma, a tumor type that was claimed largely incurable not long ago. However, therapeutic resistance to ICBs has limited their utility in the clinic. Here, we provide a commentary on recent research endeavors concerning ICB resistance in melanoma patients. This commentary highlights recent research endeavors concerning immune checkpoint blocker resistance in patients with melanoma.
ISSN:1083-7159
1549-490X
DOI:10.1093/oncolo/oyac270